Research
Hormonal
Ghrelin, the 'hunger hormone', directly stimulates reward pathways in the brain (VTA and NAc) to increase motivation and willingness to work for food, particularly palatable/high-fat foods.
Hunger isn't just an empty stomach; it's a biological signal that boosts your brain's reward system for food. This is why cravings feel so compelling. Understanding this biological drive can help separate the feeling of hunger from the act of eating.
GoodSupportsHIGH confidence
Ghrelin engages reward pathways including the mesolimbic, dopaminergic pathway. Administered to the VTA or the NAc, ghrelin increases food intake via increased dopamine... ghrelin increases an animal’s willingness to work for food by increasing motivation, arousal and foraging.
Why this rating
Supported by multiple rodent studies and one human fMRI study cited in the review.
Source
Gut peptide regulation of food intake - evidence for the modulation of hedonic feeding.
Orla Woodward et al. · Apollo (University of Cambridge) · 2021
DOI 10.17863/cam.74301
narrative_reviewCited 38×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Gut peptides (specifically GLP-1 and GIP) modulate hedonic feeding and reward-seeking behavior, extending beyond homeostatic satiety, which provides a mechanism for the significant weight loss observed with GLP-1/GIP receptor agonists.Good
- Cholecystokinin (CCK) attenuates reward-related signaling and motivation for food, acting as a satiety signal that can block the acquisition of conditioned place preference associated with rewarding stimuli.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →